Surfactant therapy for the treatment of acute respiratory distress syndrome: time to revisit?
Journal of Applied Physiology · 01.01.2026 · 140 (1) · 303-321
DOI: 10.1152/japplphysiol.00850.2025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Applied Physiology, erschienen am 01.01.2026. Verfasst von Kevin G Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Pulmonary Surfactants, Respiratory Distress Syndrome, Lung. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI).
Abstract (Originalsprache)
Pulmonary surfactant is a vital component of respiratory physiology. Surfactant homeostasis is disrupted in various pulmonary disease states, and exogenous surfactant therapy has been proposed as a treatment to improve lung function and recovery. Although this therapy has demonstrated clinically significant benefit in neonatal respiratory distress syndrome, for adult patients with acute respiratory distress syndrome (ARDS), the evidence is inconclusive. To understand the potential shortcomings of past trials and potential opportunities for more effective exogenous surfactant use in ARDS, we review in detail past trials and literature involving exogenous surfactant therapy in adult patients with ARDS. We assess various factors that may have impacted trial results and propose potential solutions and areas for future research. Advances in surfactant research suggest a potential role for exogenous surfactant therapy for adult patients with ARDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Physiology, University of Toronto, Toronto, Ontario, Canada.
- Division of Respirology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
- Toronto General Hospital Research Institute, Toronto, Ontario, Canada.
- Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York, United States.
- Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Kevin G Lee, Ewan C Goligher
Förderung
- NHLBI NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
Zitieren
APA
Lee, K. G., Greendyk, R. A., & Goligher, E. C. (2026). Surfactant therapy for the treatment of acute respiratory distress syndrome: time to revisit?. Journal of Applied Physiology, 140(1), 303-321. https://doi.org/10.1152/japplphysiol.00850.2025
Vancouver
Lee KG, Greendyk RA, Goligher EC. Surfactant therapy for the treatment of acute respiratory distress syndrome: time to revisit?. Journal of Applied Physiology. 2026;140(1):303-321. doi:10.1152/japplphysiol.00850.2025
BibTeX
@article{Lee2026,
author = {Lee, Kevin G and Greendyk, Richard A and Goligher, Ewan C},
title = {Surfactant therapy for the treatment of acute respiratory distress syndrome: time to revisit?},
journal = {Journal of Applied Physiology},
year = {2026},
volume = {140},
number = {1},
pages = {303--321},
doi = {10.1152/japplphysiol.00850.2025}
}
EUVIMED